Skip to main navigation Skip to search Skip to main content

Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk

  • Patricia A. Thompson
  • , Peter G. Shields
  • , Jo L. Freudenheim
  • , Angie Stone
  • , John E. Vena
  • , James R. Marshall
  • , Saxon Graham
  • , Rosemary Laughlin
  • , Takuma Nemoto
  • , Fred F. Kadlubar
  • , Christine B. Ambrosone
  • United States Food and Drug Administration
  • National Institutes of Health
  • University of Arizona
  • SUNY Buffalo

Research output: Contribution to journalArticlepeer-review

196 Scopus citations

Abstract

Polymorphic catechol-O-methyltransferase (COMT) catalyzes the O- methylation of estrogen catechols. In a case-control study, we evaluated the association of the low-activity allele (COMT(Met)) with breast cancer risk. Compared to women with COMT(Val/Val), COMT(Met/Met) was associated with an increased risk among premenopausal women [odds ratio (OR), 2.1; confidence interval (CI), 1.4-4.3] but was inversely associated with postmenopausal risk (OR, 0.4; CI, 0.2-0.7). The association of risk with at least one low- activity COMT(Met) allele was strongest among the heaviest premenopausal women (OR, 5.7; CI, 1.1-30.1) and among the leanest postmenopausal women (OR, 0.3; CI, 0.1-0.7), suggesting that COMT, mediated by body mass index, may be playing differential roles in human breast carcinogenesis, dependent upon menopausal status.

Original languageEnglish
Pages (from-to)2107-2110
Number of pages4
JournalCancer Research
Volume58
Issue number10
StatePublished - May 15 1998

Fingerprint

Dive into the research topics of 'Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk'. Together they form a unique fingerprint.

Cite this